Rescinnamine
Cinnasil, Moderil (rescinnamine) is a small molecule pharmaceutical. Rescinnamine was first approved as Moderil on 1982-01-01. It is used to treat hypertension in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rescinnamine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MODERIL | Mylan | N-010686 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypertension | EFO_0000537 | D006973 | I10 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02A: Antiadrenergic agents, centrally acting
— C02AA: Rauwolfia alkaloids, centrally acting antiadrenergic
— C02AA01: Rescinnamine
— C02L: Antihypertensives and diuretics in combination
— C02LA: Rauwolfia alkaloids and diuretics in combination
— C02LA02: Rescinnamine and diuretics
— C02LA52: Rescinnamine and diuretics, combinations with other drugs
HCPCS
No data
Clinical
Clinical Trials
446 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anesthesia | D000758 | 2 | 3 | 7 | 14 | 30 | 55 | ||
| Pain | D010146 | EFO_0003843 | R52 | 2 | — | — | 9 | 22 | 33 |
| Postoperative pain | D010149 | G89.18 | — | 1 | — | 7 | 16 | 24 | |
| General anesthesia | D000768 | — | 1 | 1 | 4 | 9 | 15 | ||
| Hyperalgesia | D006930 | — | 2 | — | 7 | 4 | 13 | ||
| Analgesia | D000698 | — | — | 3 | 1 | 6 | 10 | ||
| Chronic pain | D059350 | HP_0012532 | — | — | — | 3 | 4 | 7 | |
| Conscious sedation | D016292 | — | 1 | — | 2 | 4 | 7 | ||
| Bronchoscopy | D001999 | — | — | — | 2 | 5 | 7 | ||
| Cough | D003371 | HP_0012735 | R05 | — | — | — | 2 | 5 | 7 |
Show 85 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | 1 | 1 | — | 2 | 4 | |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | 1 | 1 | — | 1 | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | — | 1 | — | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | — | 1 | 2 |
| Breast diseases | D001941 | N60-N65 | — | — | 1 | — | 1 | 2 | |
| Breech presentation | D001946 | HP_0001623 | — | — | 1 | — | — | 1 | |
| Vaginal hysterectomy | D007045 | — | — | 1 | — | — | 1 | ||
| Suburethral slings | D053825 | — | — | 1 | — | — | 1 | ||
| Child development | D002657 | — | — | 1 | — | — | 1 | ||
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | — | 1 | 1 | — | — | 1 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug overdose | D062787 | 1 | 1 | — | — | 1 | 2 | ||
| Neoplasms | D009369 | C80 | 1 | 1 | — | — | 1 | 2 | |
| Hysterectomy | D007044 | EFO_0003881 | — | 1 | — | — | — | 1 | |
| Hallux valgus | D006215 | HP_0001822 | — | 1 | — | — | — | 1 | |
| Ventilator weaning | D015300 | — | 1 | — | — | — | 1 | ||
| Respiration | D012119 | 1 | 1 | — | — | — | 1 | ||
| Cesarean section | D002585 | 1 | 1 | — | — | — | 1 | ||
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Opiate overdose | D000083682 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nociceptive pain | D059226 | — | — | — | — | 7 | 7 | ||
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 3 | 3 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | — | 2 | 2 |
| Female genital diseases | D005831 | EFO_0009549 | N85 | — | — | — | — | 2 | 2 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 2 | 2 |
| Colorectal neoplasms | D015179 | — | — | — | — | 2 | 2 | ||
| Traumatic brain injuries | D000070642 | S06 | — | — | — | — | 2 | 2 | |
| Hyperventilation | D006985 | HP_0002883 | R06.4 | — | — | — | — | 2 | 2 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | — | — | 1 | 1 |
| Inguinal hernia | D006552 | HP_0000023 | K40 | — | — | — | — | 1 | 1 |
Show 58 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RESCINNAMINE |
| INN | rescinnamine |
| Description | Rescinnamine is a methyl ester, an organic heteropentacyclic compound and an indole alkaloid. It has a role as an antihypertensive agent. It derives from a hydride of a yohimban. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC |
Identifiers
| PDB | — |
| CAS-ID | 24815-24-5 |
| RxCUI | 9259 |
| ChEMBL ID | CHEMBL1668 |
| ChEBI ID | 28572 |
| PubChem CID | 5280954 |
| DrugBank | DB01180 |
| UNII ID | Q6W1F7DJ2D (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 151 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,886 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more